Study to assess the safety and efficacy of denosumab vs. placebo in children with glucocorticoid-induced osteoporosis

Update Il y a 4 ans
Reference: EUCTR2016-003083-39

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the effect of denosumab on lumbar spine bone mineral density (BMD) Z-score as assessed by dual-energy X-ray absorptiometry (DXA) at 12 months in children 5 to 17 years of age with glucocorticoid (GC)-induced osteoporosis (GiOP).


Inclusion criteria

  • Glucocorticoid-induced osteoporosis

Links